<DOC>
	<DOCNO>NCT02973100</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety investigational dos dulaglutide participant type 2 diabetes metformin monotherapy .</brief_summary>
	<brief_title>A Study Investigational Dulaglutide Doses Participants With Type 2 Diabetes Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Have type 2 diabetes ( T2D ) ≥6 month accord World Health Organization ( WHO ) classification Have HbA1c 7.0 % 10.0 % , inclusive , assessed central laboratory Have treat stable dos metformin least 3 month Have body mass index ( BMI ) ≥25 kilogram per square meter Have type 1 diabetes ( T1D ) Have use glucoselowering medication metformin 3 month prior study entry screening/leadin period use glucagonlike peptide1 receptor agonist ( GLP1 RAs ) time past Have follow cardiovascular condition : acute myocardial infarction ( MI ) , New York Heart Association Class III Class IV heart failure , cerebrovascular accident ( stroke ) Have acute chronic hepatitis , sign symptoms liver disease nonalcoholic fatty liver disease ( NAFLD ) , alanine aminotransferase ( ALT ) level &gt; 2.5 time upper limit reference range , determined central laboratory study entry ; participant NAFLD eligible participation trial Have chronic acute pancreatitis time prior study entry Have estimate glomerular filtration rate ( eGFR ) &lt; 45 milliliters/minute/1.73 square meter , calculate Chronic Kidney DiseaseEpidemiology ( CKDEPI ) equation Have serum calcitonin ≥20 picograms per milliliter , determined central laboratory study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>